Art. -Nr.: HY-W024644

Hydroxyethylthio Vitamine K3

Kundenbewertung

Based on 1 Customer Validation

Hydroxyethylthio Vitamin K3 is a Cdc25 phosphatase inhibitor, with IC₅₀ values of 4.56 μM and 23.63 μM for Cdc25A and Cdc25B, respectively. Hydroxyethylthio Vitamin K3 can be used in tumor research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 95.17%
CAS. Nr.: 59147-84-1
Formel: C₁₃H₁₂O₃S
Molecular Weight:248.30

Speicherung:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Hydroxyethylthio Vitamine K3 Chemical Structure

CAS. Nr.: 59147-84-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>10 μM Compound: 6	Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined	[PMID: 12217364]
A549	IC₅₀	41.3 μM Compound: 5	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
Detroit 551	IC₅₀	8.17 μM Compound: 6	Concentration required for 50% inhibition of growth in normal human embryonic skin fibroblast (Detroit551c) cell line was determined Concentration required for 50% inhibition of growth in normal human embryonic skin fibroblast (Detroit551c) cell line was determined	[PMID: 12217364]
DU-145	IC₅₀	22.3 μM Compound: PD8	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HepG2	IC₅₀	8.4 μM Compound: 6	Concentration required for 50% inhibition of growth in human liver hepatoblastoma (Hep G2) cell line was determined Concentration required for 50% inhibition of growth in human liver hepatoblastoma (Hep G2) cell line was determined	[PMID: 12217364]
HL-60	IC₅₀	9.3 μM Compound: 5	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
HT-29	IC₅₀	17.5 μM Compound: PD8	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
Jurkat	IC₅₀	6.8 μM Compound: 5	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
LS174T	IC₅₀	39.4 μM Compound: 5	Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MCF7	IC₅₀	30.9 μM Compound: 5	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MCF7	IC₅₀	5.19 μM Compound: 6	Concentration required for 50% inhibition of growth in mammary gland breast adenocarcinoma (MCF-7) cell line was determined Concentration required for 50% inhibition of growth in mammary gland breast adenocarcinoma (MCF-7) cell line was determined	[PMID: 12217364]
MDA-MB-231	IC₅₀	3.27 μM Compound: PD8	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
MES-SA	IC₅₀	>10 μM Compound: 6	Concentration required for 50% inhibition of growth in human multidrug resistance uterine sarcoma (MES-SA/Dx5 ) cell line was determined Concentration required for 50% inhibition of growth in human multidrug resistance uterine sarcoma (MES-SA/Dx5 ) cell line was determined	[PMID: 12217364]
MES-SA	IC₅₀	>10 μM Compound: 6	Concentration required for 50% inhibition of growth in human uterine sarcoma (MES-SA) cell line was determined Concentration required for 50% inhibition of growth in human uterine sarcoma (MES-SA) cell line was determined	[PMID: 12217364]
MKN-45	IC₅₀	5.16 μM Compound: 6	Concentration required for 50% inhibition of growth in human stomach adenocarcinoma (MKN45) cell line was determined Concentration required for 50% inhibition of growth in human stomach adenocarcinoma (MKN45) cell line was determined	[PMID: 12217364]
MONO-MAC-6	IC₅₀	6.3 μM Compound: 5	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
NPC-TW-039	IC₅₀	>10 μM Compound: 6	Concentration required for 50% inhibition of growth in human nasopharyngeal carcinoma (TW-039) cell line was determined Concentration required for 50% inhibition of growth in human nasopharyngeal carcinoma (TW-039) cell line was determined	[PMID: 12217364]
PBMC	IC₅₀	13.3 μM Compound: 5	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
SW480	IC₅₀	5.14 μM Compound: 6	Concentration required for 50% inhibition of growth in human colon adenocarcinoma (SW-480) cell line. Concentration required for 50% inhibition of growth in human colon adenocarcinoma (SW-480) cell line.	[PMID: 12217364]
SW982	IC₅₀	19.3 μM Compound: 5	Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
THP-1	IC₅₀	3.9 μM Compound: 5	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
U-937	IC₅₀	12.1 μM Compound: 5	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
WI-38	IC₅₀	7.37 μM Compound: 6	Concentration required for 50% inhibition of growth in normal human lung fibroblast (WI-38 cell line) cell line was determined Concentration required for 50% inhibition of growth in normal human lung fibroblast (WI-38 cell line) cell line was determined	[PMID: 12217364]

Chemical Information

CAS. Nr. 59147-84-1
Appearance Solid
Molecular Weight 248.30
Formel C₁₃H₁₂O₃S
Color Yellow to brown
SMILES

O=C1C(SCCO)=C(C)C(C2=C1C=CC=C2)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (402.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0273 mL

20.1367 mL

40.2734 mL

5 mM

0.8055 mL

4.0273 mL

8.0547 mL

10 mM

0.4027 mL

2.0137 mL

4.0273 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Park H, et al. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening. J Med Chem. 2008 Sep 25;51(18):5533-41. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0273 mL	20.1367 mL	40.2734 mL	100.6834 mL
	5 mM	0.8055 mL	4.0273 mL	8.0547 mL	20.1367 mL
	10 mM	0.4027 mL	2.0137 mL	4.0273 mL	10.0683 mL
	15 mM	0.2685 mL	1.3424 mL	2.6849 mL	6.7122 mL
	20 mM	0.2014 mL	1.0068 mL	2.0137 mL	5.0342 mL
	25 mM	0.1611 mL	0.8055 mL	1.6109 mL	4.0273 mL
	30 mM	0.1342 mL	0.6712 mL	1.3424 mL	3.3561 mL
	40 mM	0.1007 mL	0.5034 mL	1.0068 mL	2.5171 mL
	50 mM	0.0805 mL	0.4027 mL	0.8055 mL	2.0137 mL
	60 mM	0.0671 mL	0.3356 mL	0.6712 mL	1.6781 mL
	80 mM	0.0503 mL	0.2517 mL	0.5034 mL	1.2585 mL
	100 mM	0.0403 mL	0.2014 mL	0.4027 mL	1.0068 mL

Keywords

Hydroxyethylthio Vitamine K3

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Hydroxyethylthio Vitamine K3

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Hydroxyethylthio Vitamine K3

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Hydroxyethylthio Vitamine K3 Related Classifications

HY-W024644 Related Classifications